The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.

about

Human basonuclin 2 up-regulates a cascade set of interferon-stimulated genes with anti-cancerous properties in a lung cancer model.Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells.

P2860

Q37628005-BE263C2C-EC71-4997-BCBA-65FCDB653C73 Q48215818-7993C362-1C85-4552-884D-A6BC01620897

P2860

The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.

Item

http://www.wikidata.org/entity/Q37697141

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 October 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

The combination of MLN2238 (ix ...... hanced cell death in melanoma.

@en

The combination of MLN2238

@nl

type

Item

label

The combination of MLN2238 (ix ...... hanced cell death in melanoma.

@en

The combination of MLN2238

@nl

prefLabel

The combination of MLN2238 (ix ...... hanced cell death in melanoma.

@en

The combination of MLN2238

@nl

P1476

The combination of MLN2238 (ix ...... hanced cell death in melanoma.

@en

P2093

Alena Cristina Jaime-Ramirez

http://www.w3.org/2001/XMLSchema#string

Andrew Stiff

http://www.w3.org/2001/XMLSchema#string

Eric A Luedke

http://www.w3.org/2001/XMLSchema#string

Gregory M Kemper

http://www.w3.org/2001/XMLSchema#string

Joseph Markowitz

http://www.w3.org/2001/XMLSchema#string

Lianbo Yu

http://www.w3.org/2001/XMLSchema#string

Lorena P Suarez-Kelly

http://www.w3.org/2001/XMLSchema#string

Megan C Duggan

http://www.w3.org/2001/XMLSchema#string

Tiffany C Noel

http://www.w3.org/2001/XMLSchema#string

Vedat O Yildiz

http://www.w3.org/2001/XMLSchema#string

P2860

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

Cancer statistics, 2015

A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V

BRAF V600E is a determinant of sensitivity to proteasome inhibitors

A phase II study of bortezomib in the treatment of metastatic malignant melanoma.

A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study.

Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.

Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.

P304

81172-81186

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.12791

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27783987

http://www.w3.org/2001/XMLSchema#string

P932

5348384

http://www.w3.org/2001/XMLSchema#string

The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.

about

P2860

P2860

The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932